Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Genetron Health Targeting Liquid Biopsy, Early Cancer Detection for Future Business Growth

Genetron Health Targeting Liquid Biopsy, Early Cancer Detection for Future Business Growth

Nov 10, 2020
|
Molika Ashford
Premium

NEW YORK – Although most of the clinical testing and biopharma services Genetron Health currently provides are in the area of advanced cancer genotyping, the firm said this week that its eye is firmly on liquid biopsy testing, especially for early cancer detection and monitoring, as it maps out future technology and commercial development plans for both China and the US.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Breathe It Out

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

The Next Batch

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Switch for the Second

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.

Science Reviews How Non-Genetic DNA Features Expand Utility of Liquid Biopsies, Presents Study of Enzymes in DNA Methylation

In Science this week: review discusses advances in liquid biopsies, and more.

Apr
13
Featured Webinar

An Opportunity Arises from the Pandemic: The Promise of Targeted NGS for SARS-CoV-2 Detection

Sponsored by
Beckman Coulter Life Sciences

Mitigation of the SARS-CoV-2 pandemic will continue to require innovative solutions. This webinar will outline how Fry Laboratories rapidly redeployed a next-generation sequencing (NGS) pipeline originally created for the detection and identification of bacterial, eukaryotic, and fungal infections in response to SARS-CoV-2.

Apr
16
Featured Webinar

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Apr
21
Featured Webinar

Single-cell Multiomics Analysis of Clonal Evolution in Myeloid Malignancies

Sponsored by
Mission Bio

This webinar, the first in a “Meet the Authors” series sponsored by Mission Bio, will discuss the application of single-cell analysis to decipher clonal evolution across several stages of disease development in myeloid malignancies. 

Apr
22
Featured Webinar

Single-Cell Genomics Decodes the Developing Human Immune System

Sponsored by
10x Genomics

The human immune system is extremely complex, comprised of multiple cell types and states interacting in myriad ways to produce diverse cellular ecosystems.

What's Popular?

In Molecular Diagnostics

  1. Novacyt in Dispute with UK Department of Health and Social Care Over Coronavirus Test Contract

  2. Hologic to Acquire Finnish MDx Firm Mobidiag for Approximately $795M

  3. Invitae to Provide Genetic Testing Within eMERGE Population Screening Study

  4. Armed With $55M in New Funding, Nucleix to Further Invest in Early-Stage Lung Cancer Dx

    Premium

  5. CLIA Waiver in Hand, Binx Health Targeting Retailers, Urgent Care Centers With STI Tests

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.